20/20 BioLabs Licenses PSA Velocity Algorithm to Boost Prostate Cancer Detection — 20/20 Biolabs, Inc.

Event summary

20/20 BioLabs has exclusively licensed a PSA velocity algorithm from the University of South Carolina, developed by James Hébert, to enhance early detection of aggressive prostate cancers.
The algorithm analyzes changes in PSA levels over time, enabling earlier identification of dangerous tumors before standard PSA thresholds are crossed.
The technology will be integrated into 20/20 BioLabs’ OneTest for Cancer platform and offered as a software-as-a-service to other clinical laboratories.
20/20 BioLabs plans to collaborate with Dr. Hébert to develop similar velocity algorithms for other tumor markers like CA 125 and CA 19.9 for ovarian and pancreatic cancers.

The big picture

This licensing agreement strengthens 20/20 BioLabs’ position in the AI-powered early cancer detection market by adding a sophisticated tool for identifying aggressive prostate cancers. The deal aligns with broader industry trends toward personalized and longitudinal risk assessment in oncology, potentially setting a new standard for prostate cancer screening. The collaboration with the University of South Carolina underscores the growing role of academic institutions in driving innovation in healthcare diagnostics.

What we're watching

Algorithm Integration: How quickly 20/20 BioLabs can integrate the PSA velocity algorithm into its OneTest for Cancer platform and other clinical laboratories.
Market Adoption: Whether the algorithm will gain widespread adoption among clinical laboratories and healthcare providers for prostate cancer screening.
Future Developments: The pace at which 20/20 BioLabs and Dr. Hébert can develop similar velocity algorithms for other tumor markers, expanding the platform's capabilities.